Comparison between liraglutide monotherapy and BOT therapy with long acting insulin analogue

Comparison between liraglutide monotherapy and BOT therapy with long acting insulin analogue - Comparison between liraglutide monotherapy and BOT therapy with long acting insulin analogue

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005193

Enrollment

Registered

2011-03-04

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Changing from BOT therapy to liraglutide monotherapy. Reconversion from liraglutide monotherapy to BOT therapy after 3 months of liraglutide monotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with BOT therapy

Exclusion criteria

Exclusion criteria: Patients with severe liver or renal injury. Patients with severe infection, injury and those in the perioperative period

Design outcomes

Primary

Measure	Time frame
The levels of HbA1c and blood glucose obtained by SMBG	—

Secondary

Measure	Time frame
body weight, the frequency of hypoglycemia and lipid profiles	—

Countries

Japan

Contacts

Public ContactAtsuhito Tone

National Hospital Organization Okayama Medical Center Department of Diabetes and Metabolism

aitone@okayama3.hosp.go.jp+81-86-294-9911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026